Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 191)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Heparin |
Approved, Investigational |
Phase 4 |
|
9005-49-6 |
772 9812414 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Alpha-Heparin
Ardeparin
Ardeparin sodium
Ariven
Arteven
Bemiparin
Bemiparin sodium
Calcilean
Calciparine
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clexane
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hed-Heparin
Hep Flush Kit in plastic container
Hepalean
heparin
Heparin Cy 216
Heparin CY 216
Heparin Leo
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
|
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
Leparan
LHN 1
Lioton 1000
Lipo-hepin
Lipo-Hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Low molecular weight heparin sodium
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
Unfractionated heparin
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
2 |
|
Dalteparin |
Approved |
Phase 4 |
|
9005-49-6 |
|
Synonyms:
|
3 |
|
Tinzaparin |
Approved |
Phase 4 |
|
9041-08-1, 9005-49-6 |
25244225 |
Synonyms:
101921-26-0
102785-31-9
102-94-3
104521-37-1
11078-24-3
11129-39-8
12656-11-0
37324-73-5
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
Allocinnamic acid
alpha-Heparin
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
Certoparin
CID8784
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
Clivarin
Clivarine
CY 216
Cy 222
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
Enoxaparin sodium
Eparina
Eparina [DCIT]
Fluxum
FR 860
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
Hed-heparin
Hep Flush Kit in plastic container
heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
|
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Hep-Lock
Hep-Lock U/P
HSDB 3094
Innohep
Inno-Hep
Isocinnamic acid
Kabi 2165
KB 101
LHN 1
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
Nadroparin
Nadroparine
Novoheparin
NSC174025
Octaparin
OP 386
OP 622
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Tinzaparina
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
|
|
4 |
|
Certoparin |
Approved, Investigational |
Phase 4 |
|
|
|
5 |
|
Verteporfin |
Approved, Investigational |
Phase 4 |
|
129497-78-5 |
|
Synonyms:
3-[(23S,24R)-14-Ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶.0¹⁹,²⁴]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoate
Verteporfin
Verteporfina
|
Vertéporfine
Verteporfinum
|
|
6 |
|
Thrombin |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
coagulation factor II
Thrombin bovine
|
Thrombin, Topical (Bovine)
|
|
7 |
|
Vorapaxar |
Approved |
Phase 4 |
|
618385-01-6 |
|
Synonyms:
[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle
Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
CHEBI:586977
CHEMBL493982
|
CID 10028615
CID10077130
Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate
SCH-530348
Vorapaxar
|
|
8 |
|
Rilonacept |
Approved, Investigational |
Phase 4 |
|
501081-76-1 |
104924 |
Synonyms:
501081-76-1
D06635
interleukin-1 (IL-1) trap
|
Rilonacept
Rilonacept (USAN/INN)
|
|
9 |
|
Ranibizumab |
Approved |
Phase 4 |
|
347396-82-1 |
459903 |
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
10 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-Diethylamino-2,6-dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
Lida-Mantle
Lidocaina
|
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
Α-diethylamino-2,6-dimethylacetanilide
|
|
11 |
|
calcium heparin |
|
Phase 4 |
|
|
|
12 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
13 |
|
Heparin, Low-Molecular-Weight |
|
Phase 4 |
|
|
|
14 |
|
Terephthalic acid |
|
Phase 4 |
|
100-21-0 |
7489 |
Synonyms:
1,4-Benzenedicarboxylate
1,4-Benzenedicarboxylic acid
Benzene-p-dicarboxylate
Benzene-p-dicarboxylic acid
Disodium terephthalate
Kyselina terftalova
Para-benzenedicarboxylate
Para-benzenedicarboxylic acid
p-Benzenedicarboxylate
|
p-Benzenedicarboxylic acid
p-Dicarboxybenzene
p-Phthalate
p-Phthalic acid
p-Phthelate
p-Phthelic acid
Terephthalate
Terephthalic acid
TPA
|
|
15 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
16 |
|
Vaccines |
|
Phase 4 |
|
|
|
17 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
18 |
|
Anesthetics |
|
Phase 4 |
|
|
|
19 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
20 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
21 |
|
Colchicine |
Approved |
Phase 3 |
|
64-86-8 |
6167 2833 |
Synonyms:
(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide
30512-31-3
5843-86-7
64-86-8
7.alpha.H-Colchicine
7alphaH-Colchicine
7-alpha-H-Colchicine
AC1L1LXO
ACon1_000353
AI3-31149
AKOS001582887
BB_NC-0737
Benzo(a)heptalen-9(5H)-one
binds to tubulin
BPBio1_000535
BRD-K00259736-001-06-5
BSPBio_000485
BSPBio_002083
C 9754
C07592
C22H25NO6
C3915_SIGMA
C9754_SIGMA
CCRIS 691
CHEBI:27882
CHEMBL107
CID6167
Colchicin
Colchicin [German]
Colchicina
Colchicina [Italian]
colchicine
Colchicine
Colchicine (JP15/USP)
Colchicine (TN)
Colchicine [JAN]
Colchicine, (+-)-Isomer
Colchicine, (R)-Isomer
Colchicine, Colchicum autumnale
Colchicinum
Colchineos
Colchisol
Colchysat
Colcin
Colcrys
Colsaloid
Colstat
Condylon
CPD-9785
D003078
D00570
DB01394
DB08117
DivK1c_000753
EINECS 200-598-5
EU-0100310
Goutnil
HMS1569I07
HMS1920A08
HMS2091G16
HMS502F15
HSDB 3044
IDI1_000753
inhibits microtubular assembly
KBio1_000753
|
KBio2_001322
KBio2_003890
KBio2_006458
KBio3_001303
KBioGR_000856
KBioSS_001322
Kolkicin
LOC
Lopac0_000310
LS-279
MEGxp0_001879
MLS001055448
MLS001055448-02
MLS001304089
MLS002153786
MolPort-001-742-594
MPC-004
N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide
N-Acetyl trimethylcolchicinic acid methylether
NCGC00025125-01
NCGC00025125-02
NCGC00025125-03
NCGC00025125-04
NCGC00025125-05
NCGC00025125-06
NCGC00025125-07
NCGC00025125-11
NCGC00169157-01
NCGC00169157-02
NCGC00169157-03
NChemBio.2007.10-comp20
nchembio853-comp2
NCI60_041659
NINDS_000753
NSC 757
NSC757
Prestwick_695
Prestwick0_000363
Prestwick1_000363
Prestwick2_000363
Prestwick3_000363
S2284_Selleck
SDCCGMLS-0066633.P001
SMR000058323
SPBio_000289
SPBio_002406
Spectrum_000842
SPECTRUM1500205
Spectrum2_000075
Spectrum3_000362
Spectrum4_000298
Spectrum5_000787
spindle poison
Tocris-1364
UNII-SML2Y3J35T
UPCMLD-DP065
UPCMLD-DP065:001
WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1
ZINC00621853
|
|
22 |
|
Dialysis Solutions |
|
Phase 3 |
|
|
|
23 |
|
Protamines |
|
Phase 3 |
|
|
|
24 |
|
Photosensitizing Agents |
|
Phase 3 |
|
|
|
25 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
26 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
27 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
28 |
|
Antibodies |
|
Phase 3 |
|
|
|
29 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
Capecitabin
capecitabina
Capecitabina
capecitabine
Capecitabine
CAPECITABINE
Capécitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
capecitabinum
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
CHEBI:31348
CHEMBL1773
CID60953
|
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
R340
R-340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
|
|
30 |
|
Docetaxel |
Approved, Investigational |
Phase 1, Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
31 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
Doxo cell
Doxo-cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
32 |
|
Topotecan |
Approved, Investigational |
Phase 2 |
|
119413-54-6, 123948-87-8 |
60700 |
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
123948-87-8
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
Hydrochloride, nogitecan
Hydrochloride, topotecan
LS-127395
MLS000759456
NCGC00178695-01
NChemBio.2007.10-comp24
|
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
Nogitecan hydrochloride
NSC609699
SK And F 104864 a
SK And F104864a
SK And F-104864-a
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SmithKline beecham brand OF topotecan hydrochloride
SMP2_000312
SMP2_000327
SMR000466344
TOPO
topotecan
Topotecan
Topotecan (BAN)
Topotecan [INN:BAN]
Topotecan Hcl
Topotecan hydrochloride
Topotecan Hydrochloride
Topotecan lactone
Topotecan Lactone
Topotecan monohydrochloride, (S)-isomer
Topotecan Monohydrochloride, (S)-Isomer
TOPOTECAN, HYCAMTIN
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
UNII-7M7YKX2N15
|
|
33 |
|
Trastuzumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
180288-69-1 |
9903 |
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
Herceptin (TN)
Ig gamma-1 chain C region
RHUMAB HER2
trastuzumab
|
Trastuzumab
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
Trastuzumab (INN)
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
34 |
|
Pertuzumab |
Approved |
Phase 1, Phase 2 |
|
380610-27-5, 145040-37-5 |
2540 |
Synonyms:
2C4 Antibody
380610-27-5
D05446
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MOAB2C4
Monoclonal Antibody 2C4
Omnitarg
|
Perjeta
pertuzumab
Pertuzumab
Pertuzumab (genetical recombination)
Pertuzumab (genetical recombination) (JAN)
Pertuzumab (USAN/INN)
rhuMAb 2C4
rhuMAb-2C4
|
|
35 |
|
Temozolomide |
Approved, Investigational |
Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
85622-93-1
8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
AC1L1K9B
AC-758
BIDD:GT0204
Bio-0147
BRN 5547136
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
m & b 39831
M & B 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
|
M&B-39831
M-39831
MB 39831
Methazolastone
MLS000759447
MLS001424028
MLS002701861
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC362856
NSC-362856
SAM001246636
Sch 52365
SCH 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
SMR000466338
STK623541
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
temozolomide
Temozolomide
Témozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TL8005593
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
UNII-YF1K15M17Y
ZINC01482184
|
|
36 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
Acylpiperazine analogue, 47
AKOS005145764
AZD 2281
AZD2281
AZD-2281
|
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
olaparib
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
|
|
37 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
38 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
39 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 498142 38904 |
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
|
DivK1c_000892
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
40 |
|
Metronidazole |
Approved |
Phase 1, Phase 2 |
|
443-48-1 |
4173 |
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(Β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(Β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-(Β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitro-1-imidazoleethanol
2-methyl-5-nitroimidazole-1-ethanol
2-Methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
Acromona
AKOS000269646
Anagiardil
APMN
Apo-Metronidazole
Arilin
ARONIS24285
Atrivyl
BAS 02983617
BAY-5360
Bayer 5360
BCBcMAP01_000184
Bexon
BIDD:GT0107
Bio-0694
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
CAS-443-48-1
Caswell No. 579AA
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
Clont
Cont
CONT
CPD000058175
D00409
Danizol
DB00916
Deflamon
Deflamon-wirkstoff
Deflamon-Wirkstoff
DivK1c_000007
Efloran
EINECS 207-136-1
Elyzol
Entizol
EPA Pesticide Chemical Code 120401
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl ER
Flagyl I.V.
Flagyl I.V. RTU
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
giniflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
Hydrochloride, metronidazole
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
Metric
Metric 21
Metro Cream
Metro Gel
METRO I.V
Metro I.V.
Metro I.V. In Plastic Container
Metrocream
|
MetroCream
Metrodzhil
Metrogel
MetroGel
Metrogel-vaginal
Metrogel-Vaginal
MetroGel-Vaginal
Metrogel-vaginal (TN)
Metrogyl
Metrolag
Metrolotion
MetroLotion
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
metronidazole
Metronidazole
Métronidazole
Metronidazole (JP15/USP/INN)
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole benzoate
Metronidazole Benzoate
Metronidazole Hcl
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole in Plastic Container
Metronidazole monohydrochloride
Metronidazole Monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazole Phosphoester
METRONIDAZOLE USP
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MLS000028590
MLS000758286
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
neo-Tric
Neo-Tric
Nida
NIDA
Nidagel
NINDS_000007
Noritate
Noritate (TN)
Noritic acid
Novonidazol
NSC 50364
NSC 69587
NSC50364
NSC-50364
NSC69587
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
Prestwick_334
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Protostat
Rathimed
Rosased
RP 8823
RP-8823
S1907_Selleck
SAM001247010
Sanatrichom
Satric
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
Spectrum_001035
SPECTRUM1500412
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
STK177359
Takimetol
Trichazol
Trichex
Tricho cordes
Tricho Cordes
Trichocide
Tricho-gynaedron
Tricho-Gynaedron
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
Wagitran
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Zadstat
ZERO/004064
Zidoval
ZINC00113442
|
|
41 |
|
Dantrolene |
Approved, Investigational |
Phase 1, Phase 2 |
|
7261-97-4 |
2952 6914273 |
Synonyms:
1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione
1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin
1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin
1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione
7261-97-4
AC1OC9NE
BCBcMAP01_000067
BIDD:GT0187
BPBio1_000246
BRD-K81272440-001-02-6
BRD-K81272440-236-05-1
BRN 0705189
BSPBio_000222
BSPBio_001305
BSPBio_003074
C06939
C14H10N4O5
CHEBI:4317
CHEMBL1201288
CID6914273
D02347
Dantrium
Dantrium Intravenous
dantrolene
Dantrolene
Dantrolene (USAN/INN)
|
Dantrolene [USAN:BAN:INN]
DANTROLENE SODIUM
Dantroleno
Dantroleno [INN-Spanish]
Dantrolenum
Dantrolenum [INN-Latin]
DB01219
EINECS 230-684-8
F-368
HMS1361B07
HMS1791B07
HMS1989B07
HSDB 3050
IDI1_000898
IDI1_033775
Lopac0_000424
LS-76264
MolPort-006-389-324
NCGC00163132-01
NCGC00163402-01
NCGC00163402-02
nchembio.368-comp3
Prestwick2_000291
Prestwick3_000291
Spectrum5_001752
UNII-F64QU97QCR
ZINC26894874
|
|
42 |
|
Pioglitazone |
Approved, Investigational |
Phase 1, Phase 2 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
Actos
Actos (TN)
Actost
AD 4833
AD-4833
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
HSDB 7322
|
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
nchembio790-comp10
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
pioglitazone (INN)
Pioglitazone [Ban:Inn]
Pioglitazone [BAN:INN]
Pioglitazone [INN:BAN]
pioglitazone HCl
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazone Hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
SPBio_001897
Spectrum_001623
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
U 72107
U 72107A
U72,107A
U-72107
UNII-X4OV71U42S
Zactos
|
|
43 |
|
Clemastine |
Approved, Investigational |
Phase 1, Phase 2 |
|
15686-51-8 |
26987 |
Synonyms:
(+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-p-Chloro-a-methyl-a-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-p-Chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-Chloro-a-methyl-a-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-Chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine
(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine
14976-57-9
15686-51-8
2-(2-(1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine
2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine
AC1L1CAE
AC1Q3N52
BIDD:GT0391
BPBio1_000300
BRD-K30240666-051-05-0
BSPBio_000272
BSPBio_002045
C21H26ClNO
CAS-14976-57-9
CHEBI:3738
CHEMBL1626
CID26987
Clemastina
Clemastina [INN-Spanish]
clemastine
Clemastine
Clemastine [USAN:BAN]
Clemastine fumarate
CLEMASTINE FUMARATE
|
Clemastinum
Clemastinum [INN-Latin]
DB00283
DivK1c_000285
HMS2089I22
HS 592
HS-592
IDI1_000285
KBio1_000285
KBio3_001265
KBioGR_001570
Lopac-C-8903
LS-137531
Meclastin
Meclastine
Mecloprodin
NCGC00015281-01
NCGC00016710-01
NCGC00025168-01
NINDS_000285
Prestwick0_000306
Prestwick1_000306
Prestwick2_000306
Prestwick3_000306
SPBio_000817
SPBio_002491
Spectrum2_000689
Spectrum3_000353
Spectrum4_000955
Spectrum5_001520
Tavegyl
Tavist
Tavist (*Fumarate*)
Tocris-1453
UNII-95QN29S1ID
|
|
44 |
|
Histamine |
Approved, Investigational |
Phase 1, Phase 2 |
|
51-45-6, 75614-87-8 |
774 |
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
|
Histamine
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
β-Imidazolyl-4-ethylamine
|
|
45 |
|
Hydroxychloroquine |
Approved |
Phase 1, Phase 2 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-Chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-Chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
|
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
46 |
|
Atezolizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1380723-44-3 |
|
Synonyms:
|
47 |
|
Fluorouracil |
Approved |
Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
|
Fluorouracile [DCIT]
Fluorouracile dakota
Fluorouracile Dakota
Fluoro-uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
Fluorouracilo ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
Haemato brand OF fluorouracil
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
48 |
|
leucovorin |
Approved |
Phase 2 |
|
58-05-9 |
6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-formyltetrahydrofolate
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-formylTHF
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
|
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
L-leucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolic acid
Wellcovorin
|
|
49 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
5310940 9887054 6857599 43805 |
Synonyms:
ACT 078
ACT-078
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Eloxatine
Elplat
Foloxatine
L-OHP
L-OHP CPD
|
Oxalatoplatin
Oxalatoplatinum
oxaliplatin
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
50 |
|
Levoleucovorin |
Approved, Investigational |
Phase 2 |
|
68538-85-2 |
149436 |
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-Formyltetrahydrofolate
(6S)-5-formyltetrahydrofolic acid
(6S)-5-Formyltetrahydrofolic acid
(6S)-Folinate
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
6 S Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
ácido levofolínico
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid SF
Folinic acid-SF
Fusilev
Kunyrin
Leucoverin
|
Leucovorin
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leukovorin
Leukovorum
Levo leucovorin
Levofolene
Levofolinate
Levofolinic acid
Levoleucovorin
Levo-leucovorin
L-Folinate
L-Folinic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
Interventional clinical trials:
(show top 50)
(show all 192)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial |
Unknown status |
NCT00196417 |
Phase 4 |
Standard heparin (UFH) versus certoparin (LMWH) |
2 |
MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial |
Unknown status |
NCT01124942 |
Phase 4 |
|
3 |
Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise |
Unknown status |
NCT00476736 |
Phase 4 |
Effect on small airways (N-Acetylcystein) |
4 |
Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study |
Completed |
NCT02875028 |
Phase 4 |
Vorapaxar;Placebo |
5 |
Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial |
Completed |
NCT03169660 |
Phase 4 |
Vascular endothelial growth factor trap-eye |
6 |
An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy |
Completed |
NCT01950741 |
Phase 4 |
aflibercept |
7 |
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration |
Completed |
NCT01722045 |
Phase 4 |
Intravitreal Aflibercept Injection (IAI) |
8 |
Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy |
Completed |
NCT02072408 |
Phase 4 |
aflibercept |
9 |
Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab |
Completed |
NCT02309281 |
Phase 4 |
aflibercept 2mg |
10 |
Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) |
Completed |
NCT01663103 |
Phase 4 |
Rilonacept;Placebo |
11 |
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples |
Recruiting |
NCT01824537 |
Phase 4 |
|
12 |
Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy |
Recruiting |
NCT02621645 |
Phase 4 |
|
13 |
Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY |
Suspended |
NCT02863744 |
Phase 4 |
|
14 |
A Randomized Controlled Trial of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Community Acquired Pneumonia |
Unknown status |
NCT03185923 |
Phase 3 |
TCM plus conventional drug;TCM placebo plus conventional drug |
15 |
Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial |
Unknown status |
NCT00720967 |
Phase 3 |
|
16 |
A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema |
Completed |
NCT01783886 |
Phase 3 |
|
17 |
A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema |
Completed |
NCT01331681 |
Phase 3 |
|
18 |
A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration |
Completed |
NCT01482910 |
Phase 3 |
Visudyne |
19 |
An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema |
Completed |
NCT01512966 |
Phase 3 |
|
20 |
A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema |
Completed |
NCT01363440 |
Phase 3 |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) |
21 |
Trial to Reduce Alloimmunization to Platelets (TRAP) |
Completed |
NCT00000589 |
Phase 3 |
|
22 |
A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion |
Completed |
NCT00943072 |
Phase 3 |
Sham |
23 |
A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) |
Completed |
NCT01012973 |
Phase 3 |
|
24 |
A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia |
Completed |
NCT01249664 |
Phase 3 |
|
25 |
A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
Completed |
NCT00637377 |
Phase 3 |
Ranibizumab |
26 |
A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion |
Completed |
NCT01521559 |
Phase 3 |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) |
27 |
An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration |
Completed |
NCT00964795 |
Phase 3 |
Intravitreal Aflibercept Injection 2mg |
28 |
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration |
Completed |
NCT00509795 |
Phase 3 |
|
29 |
A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs |
Completed |
NCT02059291 |
Phase 3 |
Canakinumab;Placebo |
30 |
Indwelling Pleural Catheter for Trapped Lung: a Pilot Study for Power Calculation of a Randomized Controlled Trial Comparing Pleurocath® Versus PleurX®) |
Completed |
NCT03550027 |
Phase 3 |
|
31 |
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) |
Completed |
NCT02334748 |
Phase 3 |
canakinumab |
32 |
An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) |
Completed |
NCT02911857 |
Phase 3 |
|
33 |
A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration |
Completed |
NCT00320788 |
Phase 2 |
|
34 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 |
Completed |
NCT01739036 |
Phase 1, Phase 2 |
|
35 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP |
Completed |
NCT01142765 |
Phase 1, Phase 2 |
|
36 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone. |
Completed |
NCT01883609 |
Phase 1, Phase 2 |
|
37 |
Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. |
Completed |
NCT01666925 |
Phase 2 |
|
38 |
Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection |
Completed |
NCT01658696 |
Phase 2 |
|
39 |
A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children |
Completed |
NCT01635647 |
Phase 1, Phase 2 |
|
40 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS |
Completed |
NCT01623557 |
Phase 1, Phase 2 |
|
41 |
Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP |
Completed |
NCT00890760 |
Phase 1, Phase 2 |
|
42 |
An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). |
Completed |
NCT01242813 |
Phase 2 |
ACZ885 |
43 |
OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. |
Completed |
NCT01802684 |
Phase 2 |
|
44 |
Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
Completed |
NCT00436501 |
Phase 1, Phase 2 |
docetaxel |
45 |
A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP |
Completed |
NCT03707353 |
Phase 1, Phase 2 |
|
46 |
Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) |
Completed |
NCT00582907 |
Phase 2 |
Rilonacept;Placebo |
47 |
A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma |
Completed |
NCT00450255 |
Phase 2 |
|
48 |
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma |
Completed |
NCT00357760 |
Phase 2 |
|
49 |
A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer |
Completed |
NCT00327171 |
Phase 2 |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
50 |
Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis |
Completed |
NCT00094900 |
Phase 2 |
IL-1 Trap |
|